SkinBioTherapeutics PLC Expanded enrolment for AxisBiotix-Ps(TM) study (4563N)
February 01 2021 - 2:00AM
UK Regulatory
TIDMSBTX
RNS Number : 4563N
SkinBioTherapeutics PLC
01 February 2021
1 February 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Expanded enrolment for AxisBiotix-Ps(TM) food supplement
consumer study
-- Study size increased to 250 from 200, following high demand for places
-- Study to commence by end February 2021
-- Participants' feedback on AxisBiotix-Ps(TM) to be monitored through smart devices
SkinBioTherapeutics plc (AIM: SBTX ) , a life science company
focused on skin health, announces that AxisBiotix Limited, a wholly
owned subsidiary of the Company, has increased the size of its food
supplement consumer study from 200 to 250 participants, following a
high level of demand .
Further to research exploring the relationship between the gut
and the skin, SkinBioTherapeutics with its partner Winclove
Probiotics B.V., developed a blend of bacterial strains in the form
of a food supplement. The proprietary blend of bacterial strains
has been specifically designed to balance the gut microbiome to
address the over-production of new skin cells often seen in
aggressive skin conditions such as psoriasis.
Enrolment for the 'self-managed' food supplement consumer study
commenced 13 January 2021, via a dedicated website
www.axisbiotix.com . There has been a high level of demand for
places and consequently, the Company has extended the study size
from its initial target.
The study will be monitored through a mobile device app,
involving periodic questions for participants evaluating the
progression of their symptoms, and the submission of photographs of
affected areas.
Winclove is expecting to ship the product to the Company by
mid-February. The supplements will then be dispatched to the study
participants, with an expected study start date by the end of
February 2021. The study will conclude before the end of April 2021
and the Company expects to be able to report on the study findings
shortly thereafter.
Subject to a positive outcome, the Company will then target a
commercial launch of the product during the course of 2021.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"I am overwhelmed by the response to the study. We received an
extraordinary number of applicants in a very short period of time,
the majority of which were psoriasis sufferers.
"The high demand for places on the study underlines just how
prevalent skin conditions such as psoriasis are, and how keen
sufferers are to try something new and natural to alleviate their
symptoms. If we can, we want to help as many people as
possible.
"We now move to the formal commencement of the study in the
coming weeks and look forward to working with the applicants with
the aim of seeing positive progression of their symptoms."
-Ends-
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
/ Nathan Billis SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSDMFWFEFSEEF
(END) Dow Jones Newswires
February 01, 2021 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024